# Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/dupilumab-shows-long-term-safety-and-efficacy-in-patients-with-moderate-to/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Mette Deleuran,Diamant Thaçi,Lisa A. Beck,Marjolein de Bruin‐Weller,Andrew Blauvelt,Seth Forman,Robert Bissonnette,Kristian Reich,Weily Soong,Iftikhar Hussaın,Peter Foley,Michihiro Hide,Jean‐David Bouaziz,Joel M. Gelfand,Lawrence Sher,Marie L. A. Schuttelaar,Chen Wang,Zhen Chen,Bolanle Akinlade,Abhijit Gadkari,Laurent Eckert,John D. Davis,Manoj Rajadhyaksha,Heribert Staudinger,Neil M.H. Graham,Gianluca Pirozzi,Marius Ardeleanu |
| Citations | 257 |
| DOI | 10.1016/j.jaad.2019.07.074 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.jaad.org/article/S019096221932465X/pdf |
| OpenAlex ID | https://openalex.org/W2965009353 |
| PMID | 31374300 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Marie L. A. Schuttelaar](https://scholariq.org/researchers/marie-l-a-schuttelaar/)
- [Abhijit Gadkari](https://scholariq.org/researchers/abhijit-gadkari/)
- [Joel M. Gelfand](https://scholariq.org/researchers/joel-m-gelfand/)
- [Marius Ardeleanu](https://scholariq.org/researchers/marius-ardeleanu/)

## Paper primary topic

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

## Paper topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.